NbN3 app not working? crashes or has problems?

NbN3 Status


I have a problem with NbN3

Are you having issues? Select the issue you are having below and provide feedback to NbN3.




Have a Problem with NbN3? Report Issue




Common NbN3 Problems & Solutions. Troubleshooting Guide

Complete guide to troubleshoot NbN3 app on iOS and Android devices. Solve all NbN3 app problems, errors, connection issues, installation problems and crashes.


Table of Contents:

  1. NbN3 iPhone Issues and Solutions

  2. NbN3 Android App Issues and Solutions
       


  Contact Support

Some issues cannot be easily resolved through online tutorials or self help. So we made it easy to get in contact with the support team at European College of Neuropsychopharmacology (ECNP), developers of NbN3.




About this app

Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients. • Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature. • The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”. • In this second edition 22 new medications were added so NbN includes now 130 medications.  It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions.  This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.  The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action.  Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.  But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion.  Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data.  For those who would like to know more abo derived from empirical data. ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.  We need to treat our patients now, and we cannot postpone treatment until all the facts are known.  Approved Indications – based on the recommendations of major regulatory bodies (e. g. FDA, EMA, etc.  As this is on-going process, we recognize that the product is imperfect.  Neurobiology – This dimension is focused on the biology.  Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e. g. later editions) will be undertaken.